Evidence map›Paper›PMID 28724554›Full record

ArticleJournal of clinical microbiology2017

Prevalence of Human Papillomavirus in Self-Taken Samples from Screening Nonattenders.

J U H Lam, M Rebolj, D M Ejegod, H Pedersen, C Rygaard, E Lynge, E Harder, L T Thomsen, S K Kjaer, J Bonde

Abstract read
In one paragraph

Article in Journal of clinical microbiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

J U H LamDepartment of Pathology, Copenhagen University Hospital Hvidovre, Hvidovre, Denmark.
M ReboljClinical Research Centre, Copenhagen University Hospital Hvidovre, Hvidovre, Denmark.ORCID 0000-0001-9597-645X
D M EjegodDepartment of Pathology, Copenhagen University Hospital Hvidovre, Hvidovre, Denmark.
H PedersenDepartment of Pathology, Copenhagen University Hospital Hvidovre, Hvidovre, Denmark.
C RygaardDepartment of Pathology, Copenhagen University Hospital Hvidovre, Hvidovre, Denmark.
E LyngeDepartment of Public Health, University of Copenhagen, Copenhagen, Denmark.
E HarderUnit of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark.
L T ThomsenUnit of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark.
S K KjaerUnit of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark.
J BondeDepartment of Pathology, Copenhagen University Hospital Hvidovre, Hvidovre, Denmark jesper.hansen.bonde@regionh.dk.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Copenhagen Self-Sampling Initiative (CSi) has shown how human papillomavirus (HPV)-based self-sampling can be used to increase screening participation among 23,632 nonattenders in the Capital Region of Denmark. In this study, we describe HPV prevalence and genotype frequency in 4,824 self-samples as determined by three HPV assays (the CLART, Onclarity, and Hybrid Capture 2 [HC2] assays) and compare the results with those for physician-taken follow-up samples. The HPV self-sample findings were also compared to the findings for a reference population of 3,347 routinely screened women from the Horizon study, which had been undertaken in the same screening laboratory. Nonattenders had an HPV prevalence of 11.3% as determined by the CLART assay, which was lower than that for women from the Horizon study (18.5%). One-third of the CSi women who tested HPV positive by self-sampling tested HPV negative on the physician-taken follow-up sample. The CLART and Onclarity assays agreed on 64% (95% confidence interval [CI], 60 to 68%) of the HPV-positive self-taken samples. When the HC2 assay results were added into a three-way comparison, the level of agreement decreased to 27% (95% CI, 24 to 29%). Our findings suggest that further validation of HPV assays on self-taken samples is needed for optimal HPV detection and correct clinical management of HPV-positive women.

Indexed as

Patient ComplianceAdultAgedDenmarkDNA, ViralFemaleHumansMass ScreeningMiddle AgedPapillomaviridaePapillomavirus InfectionsPrevalenceSelf CareUterine Cervical DysplasiaUterine Cervical NeoplasmsVaginal SmearsDNA, ViralHPV assaysHPV self-samplingnonattendersprimary screening

Identifiers

PMID28724554
PMCPMC5625377

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.